All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
5 warning events since 2021; the latest 2025-10-03.
From the record
Xilio Therapeutics, Inc.'s filings since 2021 show 5 warning events: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2025-10-03) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
SI estimate 5.1/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Xilio Therapeutics, Inc.'s track record is put at 5.1 of 10 with a confidence of 20 of 100, because fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 324 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
How has it treated the people who own it?
SI estimate 2.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Xilio Therapeutics, Inc.'s shareholder treatment is put at 2.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 28% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -99%: lost 99¢ per shareholder dollar. Leverage 77%: owes 77¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Xilio Therapeutics, Inc. lost about 99 cents for every dollar of shareholders' money. Leverage: it owed about 77 cents per dollar of assets, and net share issuance: its share count grew 118.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 31% of 315 in its family; net margin -80.1%.
From the record
Xilio Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $44 million in fiscal 2025 ranks in the top 46% by size; a net margin of -80.1% ranks in the top 44%; revenue growth of 590.8% a year over the last 1 filed years ranks in the top 3% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 36% of 315 in its family for leadership; chief executive since 2021.
From the record
Xilio Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Russo, Rene (PRESIDENT AND CEO, as filed), filing under that title since 2021-10-21, 5.1 years (bottom 48% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 3.3 years (bottom 18%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 42%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 30% of 273 in its family for room to expand.
From the record
Xilio Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $139 million against no long-term debt tagged leaves 90.1% of its assets as net cash, top 10% of its family; cash from operations less capital spending is -12.6% of revenue (top 34%); research spending of 128% of revenue (top 47%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
SI estimate 5.0/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Xilio Therapeutics, Inc.'s growth drivers is put at 5.0 of 10 with a confidence of 20 of 100, because the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 307 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
Did its newest year beat what its own record pointed to?
SI estimate 5.3/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Xilio Therapeutics, Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made